COMMUNIQUÉS West-GlobeNewswire

Prime Medicine to Participate in Upcoming Investor Conferences
07/10/2025
CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
07/10/2025
NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D [...]
Kestra Appoints Timothy Moran as Chief Business Officer, Strengthening Leadership Team for Next Stage of Growth
07/10/2025
KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief [...]
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025
07/10/2025
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as a Poster of Distinction [...]
Extendicare Announces Timing of 2025 Third Quarter Results and Conference Call
07/10/2025
MARKHAM, Ontario, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the third quarter of 2025 after market [...]
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
07/10/2025
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics [...]
TerrAscend to Host Third Quarter 2025 Earnings Conference Call
07/10/2025
TORONTO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]
Bluejay Therapeutics Announces Data Presentations in Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at Upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025
07/10/2025
REDWOOD CITY, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver [...]
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
07/10/2025
Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readiness BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage [...]
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025
07/10/2025
ROCKVILLE, Md. and SUZHOU, China, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“ Ascentage Pharma ” or the “ Company ”), a global, commercial stage, integrated [...]
Resalis Therapeutics Reports Durable, Fat-Selective Weight Loss with RES-010 in Non-Human Primates at Multiple Scientific and Industry Meetings
07/10/2025
Torino, Italy, October 7 – Resalis Therapeutics , a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense [...]
New Data Presented on Givinostat for Treatment of Duchenne Muscular Dystrophy at 2025 World Muscle Society Congress
07/10/2025
Long-term treatment with givinostat in boys with Duchenne muscular dystrophy continues to show a favourable safety and tolerability profile Consistent efficacy demonstrated across age groups MILAN, Italy, October 07, [...]
Salipro Biotech Strengthens Global IP Portfolio with Two New Japanese Patents
07/10/2025
The two new patents expand protection for Salipro Biotech's proprietary technology for stabilizing and extracting challenging membrane proteins, crucial for developing therapeutics against high-value drug targets like [...]
Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer
07/10/2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, [...]
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
07/10/2025
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]
Cellectis présentera des données sur son programme de thérapie génique non-virale et sur des TALE Base Editors lors du congrès annuel de l’ESGCT
07/10/2025
NEW YORK, 07 oct. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des [...]
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
07/10/2025
Former GSK and Sanofi executive, led Cervarix ® development and advanced pioneering therapies for rare diseases, decade of experience as venture capitalist Strengthens Bioxodes leadership following encouraging Phase 2a [...]
Bioxodes nomme Philippe Monteyne, un vétéran de l’industrie pharmaceutique, au poste de président et accélère le développement en phase avancée de son candidat médicament innovant dans l’AVC
07/10/2025
Ancien dirigeant de GSK et de Sanofi, M. Monteyne a supervisé le développement de Cervarix ® et permis l’avancement de plusieurs traitements pionniers dans les maladies rares ; il apporte dix années d’expérience en [...]
Allegro showcases superior shock-absorbing capacity of injectable hydrogel for osteoarthritis at CellMech
07/10/2025
Comparative testing against four market-leading hydrogels demonstrates Hydrocelin’s superior shock absorbing capacity Significantly improves the shock-absorbing capacity of pathological equine synovial fluid in [...]

Pages